Financials data is unavailable for this security.
View more
Year on year Haw Par Corporation Ltd grew revenues 27.44% from 182.09m to 232.06m while net income improved 46.02% from 148.32m to 216.57m.
| Gross margin | 57.06% |
|---|---|
| Net profit margin | 98.06% |
| Operating margin | 102.07% |
| Return on assets | 6.41% |
|---|---|
| Return on equity | 6.61% |
| Return on investment | 6.61% |
More ▼
Cash flow in SGDView more
In 2023, Haw Par Corporation Ltd increased its cash reserves by 71.84%, or 239.78m. Cash Flow from Investing totalled 258.01m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 62.68m in cash from operations while cash used for financing totalled 79.30m.
| Cash flow per share | 1.09 |
|---|---|
| Price/Cash flow per share | 10.29 |
| Book value per share | 16.70 |
|---|---|
| Tangible book value per share | 16.65 |
More ▼
Balance sheet in SGDView more
| Current ratio | 4.67 |
|---|---|
| Quick ratio | 4.49 |
| Total debt/total equity | 0.0098 |
|---|---|
| Total debt/total capital | 0.0097 |
More ▼
Growth rates in SGD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 46.02%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.95% |
|---|---|
| Div growth rate (5 year) | 5.92% |
| Payout ratio (TTM) | 37.77% |
| EPS growth(5 years) | 3.83 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 33.92 |
More ▼
